Rejoy Health vs Moderna

Side-by-side comparison of AI visibility scores, market position, and capabilities

Moderna leads in AI visibility (90 vs 38)
Rejoy Health logo

Rejoy Health

EmergingHealthcare

General

SF YC W21 AI patient education for thyroid and chronic conditions at $125M valuation Sep 2024; $22.2M from Google, Harvard endowment, Gaingels/YC competing with Paloma Health for AI-driven medical knowledge accessibility for underdiagnosed chronic...

AI VisibilityBeta
Overall Score
D38
Category Rank
#465 of 596
AI Consensus
80%
Trend
stable
Per Platform
ChatGPT
38
Perplexity
34
Gemini
35

About

Rejoy Health is a San Francisco-based AI-powered healthcare platform — backed by Y Combinator (W21) with $22.2 million in total funding from Y Combinator, Google, Gaingels, and the Harvard University endowment fund, achieving a $125 million valuation in September 2024 — providing patients with chronic conditions (particularly thyroid disorders) with AI-driven medical knowledge accessibility tools and subscription-based treatment and management services that bridge the gap between patient symptoms, lab results, and clinical recommendations. Founded in 2020 by former Facebook and Microsoft engineers and launched through Y Combinator, Rejoy translates complex medical information into personalized, understandable patient guidance using artificial intelligence.

Full profile
Moderna logo

Moderna

LeaderHealthcare Tech

Enterprise

mRNA pioneer with $3.2B FY2024 revenue (down from $18.4B 2022 COVID peak); mRESVIA RSV vaccine approved 2024; personalized cancer vaccine with Merck shows 44% recurrence reduction in melanoma.

AI VisibilityBeta
Overall Score
A90
Category Rank
#2 of 596
AI Consensus
83%
Trend
up
Per Platform
ChatGPT
92
Perplexity
93
Gemini
89

About

Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stéphane Bancel, and others in Cambridge, Massachusetts, where it is headquartered and trades on Nasdaq (MRNA). The company achieved extraordinary commercial success with Spikevax, its COVID-19 mRNA vaccine developed in partnership with the U.S. government in 2020—generating $18.4 billion in COVID vaccine revenues in 2022 at peak—before experiencing a severe revenue decline as global COVID booster demand normalized. For FY2024, Moderna generated approximately $3.2 billion in revenues, with Spikevax and the reformulated XBB.1.5-targeting COVID vaccine contributing the majority, while the company's significant R&D investment pipeline consumed most operating cash flows.

Full profile

AI Visibility Head-to-Head

38
Overall Score
90
#465
Category Rank
#2
80
AI Consensus
83
stable
Trend
up
38
ChatGPT
92
34
Perplexity
93
35
Gemini
89
39
Claude
96
42
Grok
95

Key Details

Category
General
Enterprise
Tier
Emerging
Leader
Entity Type
brand
company

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.